Search PubMed⌕ Search

Biomedical subjects

M Buemi

Publications and source records attributed to M Buemi.

133 records · Page 8Linked to original sources
PubMedDate not supplied

Changes in plasma concentrations of atrial natriuretic peptide during the first ten days and the second month of life.

Atrial natriuretic peptide (ANP) was assayed on the 1st, 3rd, 7th and 10th day of extrauterine life and the levels of the hormone were checked after the 2nd month in 12 infants. After an initially rapid increase, with a peak of the 3rd day (45.7 +/- 7 pg/ml the 1st day of extrauterine life and 175 +/- 5 pg/ml on the 3rd day), we can recognise a progressive decrease until the measurement made at 2 months (61.5 +/- 5 pg/ml). The reported data show the important role of ANP in adaption of life after birth. This can be considered as a compensatory response because it represents an attempt to maintain the balance of positive sodium which is essential for the growth of the newborn.

Atrial Natriuretic Factor↗
PubMedDate not supplied

[Amylasemia in uremics: a complex interpretation].

Plasmatic amylase increases quite often in uremia. Hyperparathyroidism is also present in uremic patients and it is thought to be the main factor of an increased of amylase; its effect is mediated by an increase of cytosolic calcium. The authors measured the plasmatic level of amylase, lipase, calcium phosphates and parathormone before and after administration of Ca-antagonists (Verapamil and Diltiazem). The results did not shown any correlation. Hyperparathyroidism increased the pancreatic secretion but don't influences the amount of enzymes.

Adult↗
PubMedDate not supplied

Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients.

The authors evaluated the possibility that the time of the administration of erythropoietin (rHuEPO) may play any effect on the therapeutic outcome of the treatment. The study was carried out on 26 uremic subjects submitted to hemodialysis in the morning or in the evening. At the end of the dialytic treatment every patient was administered rHuEPO IV. The amount of erythropoietin needed to reach an Ht value of 32% was evaluated. The subjects whose rHuEPO had been administered in the first evening hours showed that they needed a less quantity of rHuEPO (885 +/- 50 vs 1550 +/- 75 IU/Kg; p < 0.01), and showed a more rapid improvement of the anemia. According to the lans of a physiologic circadian rhythm, the evening i.v. administration of rHuEPO seems to insure a quicker therapeutic success.

Aged↗
PubMedDate not supplied

[Rapid, progressive deterioration of renal function following erroneous administration of high doses of subcutaneous recombinant erythropoietin].

It's reported a case of progressive and rapid deterioration of the renal function, following to a wrong administration of high doses of recombinant erythropoietin. After the administration of 10,000 U of rHuEPO three times a week for at least five times instead of the 1000 U ordered, the patient showed a progressive increase of the plasmatic creatinine values from 2.2 to 3.3 mg/dl. In the same period we pointed out an increase of hematocrit (from 29% to 35%) and of the Hb (from 9.3 to 11.2 g/dl). The patient, suffering from a slightly high blood pressure, furthermore showed important pressure increases. The suspension of the treatment by erythropoietin permitted the restoration of the creatinine values to levels similar to the ones pointed out before the treatment and a reduction of the blood pressure values. The AA. think that a too rapid regression of the anaemia achieved by a rHuEPO treatment can condition a worsening of the renal function in the pre uraemic patient.

Aged↗
PubMedDate not supplied

Rapid and transient lymphocytopenia after i.v. administration of high doses of human recombinant erythropoietin.

The effect of administration of human recombinant erythropoietin on leukocytic cells has been evaluated. In humans the administration of 20,000 U i.v. of rHuEPO caused a rapid and transitory leukopenia that seemed to be caused by a preferential reduction of lymphocytes (2715 +/- 513 mm3 t 0; 1898 +/- 506 t 60', p < 0.002). Pretreatment with imidazole-2-hydroxybenzoate, a drug capable of inhibiting the synthesis of prostaglandins, caused a less marked and later reduction of lymphocytes (2242 +/- 477 t 0; 1560 +/- 318 t 180 minutes, p < 0.001). A less marked and later lymphocytopenia was also shown in subjects affected by chronic renal insufficiency (2907 +/- 726 t 0; 1944 +/- 512 t 180 minutes, p < 0.005).

Erythropoietin↗